Press releases

At the DDF Summit 2026 in Berlin, Disruptive Pharma presented an award-winning poster on Formulite®, our bioavailability enhancement platform for poorly soluble oral drugs. The poster, which won the 2026 Poster Competition, summarizes technical and clinical validation data, including improved dissolution, higher drug loading, bioavailability...

During a visit to a potential partner, the objective was to rapidly assess the feasibility of formulating a poorly soluble compound using Formulite® — and generate material for downstream development without entering a lengthy formulation program. Approach focused, on-site development sprint was conducted over two days, combining feasibility...

We are pleased to welcome Ellen Brunzell to Disruptive Pharma. Ellen is a licensed pharmacist and recently completed her PhD in pharmaceutical physical chemistry at Uppsala University. Her research has focused on drug substances, formulation-relevant interactions and peptide aggregation, bringing valuable expertise to our work in pharmaceutical...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement regarding active operations. In accordance with applicable rules, Nasdaq may therefore delist the Company’s financial instruments...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.